What the label lists and what reports show
Ibandronate side effects
Ibandronate's FDA label: “The most common adverse reactions (greater than 5%) are back pain, dyspepsia, pain in extremity, diarrhea, headache, and myalgia.” FAERS holds 3,078 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is arthralgia (261 reports).
- Generic listed
Check it at the source: the ibandronate FDA label on DailyMed (effective March 18, 2026, Aurobindo Pharma Limited); the FDA FAERS public dashboard.
What does the patient leaflet say about side effects?
From the patient leaflet: What are the possible side effects of ibandronate sodium tablets?Ibandronate sodium tablets may cause serious side effects. See “What is the most important information I should know about ibandronate sodium tablets?” The most common side effects of ibandronate sodium tablets are: Back pain Heartburn Stomach area (abdominal) pain Pain in your arms and legs Diarrhea Headache Muscle pain Flu-like symptoms You may get allergic reactions, such as hives, breathing difficulties, swelling of your face, lips, tongue or throat, or feeling faint. Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of ibandronate sodium tablets. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Aurobindo Pharma USA, Inc. at 1-866-850-2876. […]
Source: FDA drug label, Aurobindo Pharma Limited, effective March 18, 2026 (SPL set 86c0b4ae-5e38-4efe-88af-50ac560e294f), via openFDA; the full label on DailyMed
What does the label list?
From the label: adverse reactionsThe most common adverse reactions (greater than 5%) are back pain, dyspepsia, pain in extremity, diarrhea, headache, and myalgia.
Table 2 Adverse Events with an Incidence of at Least 2% in Patients Treated with Ibandronate Sodium 2.5 mg (ibandronate) Daily or Ibandronate Sodium 150 mg (ibandronate) Once-Monthly for Treatment of Postmenopausal…
| Body System/Adverse Event | Ibandronate Sodium 2.5 mg (ibandronate) Daily % (n=395) | Ibandronate Sodium 150 mg (ibandronate) Monthly % (n=396) |
|---|---|---|
| Hypertension | 7.3 | 6.3 |
| Dyspepsia | 7.1 | 5.6 |
| Nausea | 4.8 | 5.1 |
| Diarrhea | 4.1 | 5.1 |
| Constipation | 2.5 | 4 |
| Abdominal Pain a | 5.3 | 7.8 |
| Arthralgia | 3.5 | 5.6 |
| Back Pain | 4.3 | 4.5 |
| Pain in Extremity | 1.3 | 4 |
| Localized Osteoarthritis | 1.3 | 3 |
| Myalgia | 0.8 | 2 |
| Muscle Cramp | 2 | 1.8 |
| Influenza | 3.8 | 4 |
| Nasopharyngitis | 4.3 | 3.5 |
| Bronchitis | 3.5 | 2.5 |
| Urinary Tract Infection | 1.8 | 2.3 |
| Upper Respiratory Tract Infection | 2 | 2 |
| Headache | 4.1 | 3.3 |
| Dizziness | 1 | 2.3 |
| Influenza-like Illness b | 0.8 | 3.3 |
| Rash c | 1.3 | 2.3 |
| Insomnia | 0.8 | 2 |
Rows and numbers as the label prints them, under its own column headings (the first rows of a longer table where it runs on). A reaction in a trial table is not necessarily caused by the medicine, and trials differ from everyday use.
From the label: adverse reactions, continuedThe following clinically significant adverse drug reactions are described elsewhere in the labeling: Upper Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.1) ] Hypocalcemia and Mineral Metabolism [see Warnings and Precautions (5.2) ] Musculoskeletal [see Warnings and Precautions (5.3) ] Jaw Osteonecrosis [see Warnings and Precautions (5.4) ] Atypical Fractures Including Femoral Fractures [see Warnings and Precautions (5.5) ] Severe Renal Impairment [see Warnings and Precautions (5.6) ] The most common adverse reactions (greater than 5%) are back pain, dyspepsia, pain in extremity, diarrhea, headache, and myalgia. (6) To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Treatment and Prevention of Postmenopausal Osteoporosis Daily Dosing The safety of ibandronate sodium 2.5 mg (ibandronate) once daily in the treatment and prevention of postmenopausal osteoporosis was assessed in 3577 patients aged 41 to 82 years. …
Source: FDA drug label, Aurobindo Pharma Limited, effective March 18, 2026 (SPL set 86c0b4ae-5e38-4efe-88af-50ac560e294f), via openFDA; the full label on DailyMed
What do FAERS reports show?
3,078 reports list ibandronate among the medicines taken, each a report of something that happened, not proof the medicine caused it; 295 are coded as a death and 688 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Of the 22 reactions below, 12 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.
Reports received each year
The 25 most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms
What next?
- Ibandronate: the full record
- label, generics, price, shortages, recalls
- Report a side effect to the FDA
- MedWatch
- Side effects hub
- the most reported medicines and reactions